TPG Capital LP has been exploring a sale Aptalis pharmaceutical company, a specialty pharmaceutical company owned since 2008, worth more than 30 billion U.S. dollars, four people familiar with the matter said on Wednesday.
Private equity firm has been working with JPMorgan Chase & Co. And EVERCORE partner companies looking for buyers Montreal pharmaceutical company is undergoing months has been in the sales process, said the source, who asked not to be named because the matter is confidential.
Some potential buyers think TPG over $ 30 billion asking price is high, and decided not to bid, it is unclear whether there will be a deal, two sources said.
Indian drugmaker Sun Pharmaceutical Industries Ltd. and North Carolina Raleigh, Salix Pharmaceuticals companies, took a look, but no longer in pursuit of an agreement, two sources said.
Elan Corporation and Forest Laboratories is also considering a bid Aptalis Earlier this year, before exiting for different reasons, and the third person familiar with the matter said.
Elan Royalty medicine hostile takeover theme and in July agreed to sell itself to the U.S. drugmaker Perrigo Company is a $ 860 million U.S. dollars. Forests in May announced that its long-time CEO, will retire at the end of the year.
TPG may also consider other options, such as an initial public offering of shares or dividend recapitalization should deal can not be achieved, the sources added.
As Aptalis, Sun Pharma and Forest Laboratories representatives did not immediately respond to requests for comment. TPG, Elan, Salix, JP Morgan Chase (JPMorgan) and EVERCORE's declined to comment.
In health care is the most active private equity investor, TPG, bought a $ 130 million U.S. dollars, in 2008, formerly known as AXCAN pharmaceutical, pharmaceutical companies, pharmaceutical juhlander merged in 2011. The combined company changed its name to Aptalis.
Specialty pharmaceutical company, there are some medications cystic fibrosis and gastrointestinal disorders, primarily in North America and Europe, sales of products.
In fiscal year 2012, Aptalis expected to have 615 million yuan of income and adjusted earnings before interest, taxes, depreciation and amortization earnings (EBITDA) 2.69 billion, according to its website.
A potential sales are exploring, there is a transaction in the pharmaceutical sector in the past few months has been a flurry.
In other trading, this year saw Actavis Company's $ 500 million U.S. dollars acquisition of Dublin-based Chinese  special PLC's announcement, and the value of $ 870 million acquisition of eye care company Bausch & Lomb holding international generic drug .
 



Other News:
Islamist militants attack Somali capital, plan more before Ramadan ends
TPG explores $3 billion sale of specialty drugmaker Aptalis
Roche cancer drug suffers patent setback in India
Duke profit falls on write-down, mild weather
Egypt news agency confirms envoys met Shater
Berlusconi conviction leaves Italian government hanging
Thirty killed in heavy fighting in Syrian mountains
U.S. shutdown battle begins as Republicans kill spending measure